SCHEMBL2085303

SCHEMBL2085303

CCOC(=O)c1sc(-c2ccc(OC)cc2)nc1C

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.73
DBF4 Q9UBU7 7/20 0.73
PTPN11 Q06124 1/20 0.64
TRPM8 Q7Z2W7 4/20 0.61
ALDH1A1 P00352 3/20 0.60
RXFP1 Q9HBX9 2/20 0.60
NPC1 O15118 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
POLB P06746 1/20 0.59
GAA P10253 1/20 0.59
KDM4E B2RXH2 4/20 0.59
MAPT P10636 3/20 0.59
LMNA P02545 1/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
RAB9A P51151 2/20 0.55
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28297246 0.90 CDC7 (0.71) CDC7DBF4PTPN11TRPM8ALDH1A1
SCHEMBL892889 0.89 CDC7 (0.77) CDC7DBF4TRPM8ALDH1A1GAA
SCHEMBL290306 0.89 ALDH1A1 (0.59) CDC7DBF4PTPN11TRPM8ALDH1A1
SCHEMBL28295659 0.88 CDC7 (0.57) CDC7DBF4PTPN11TRPM8ALDH1A1
SCHEMBL28295534 0.88 PTPN11 (0.63) CDC7DBF4PTPN11TRPM8ALDH1A1
SCHEMBL290384 0.87 CDC7 (0.75) CDC7DBF4PTPN11TRPM8ALDH1A1
SCHEMBL2880861 0.87 CDC7 (0.67) CDC7DBF4TRPM8ALDH1A1NPC1
SCHEMBL5070783 0.87 CDC7 (0.67) CDC7DBF4PTPN11TRPM8ALDH1A1
SCHEMBL14109854 0.86 RXFP1 (0.60) CDC7DBF4PTPN11ALDH1A1RXFP1
SCHEMBL2823339 0.86 CDC7 (0.73) CDC7DBF4TRPM8ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107151243-B 2-substituted-4-methyl-5- (4, 5-dihydrothiazole-2-yl) -1, 3-thiazole compounds, preparation method and biological activity evaluation thereof 江苏海洋大学 2020-09-08 CN disclosed
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
CN-109810071-A A kind of miRNA biosynthesis inhibitor 中国科学院成都生物研究所 2019-05-28 CN disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
EP-1984360-B1 Compounds and methods for modulating FX-receptors LILLY CO ELI (US) 2014-01-15 EP disclosed
US-7863302-B2 Compounds and methods for modulating FX-receptors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
US-7846960-B2 FXR agonists ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-2029547-B1 FXR AGONISTS LILLY CO ELI (US) 2010-04-28 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007140183-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed
WO-2007092751-A2 COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-16 WO disclosed
EP-0321115-B1 CARBOXAMIDE DERIVATIVES HAVING TETRAZOLE AND THIAZOLE RINGS AND THEIR USE SAWAI PHARMACEUTICAL CO., LTD. (JP) 1991-08-14 EP disclosed
US-4946855-A ANTIALLERGIC SAWAI PHARMACEUTICAL CO., LTD. (JP) 1990-08-07 US disclosed
EP-0321115-A1 Carboxamide derivatives having tetrazole and thiazole rings and their use SAWAI PHARMACEUTICAL CO., LTD. (JP) 1989-06-21 EP disclosed
US-4558059-A ANTI-PEPTIC ULCER AGNET KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1985-12-10 US disclosed
EP-0051409-B1 2-(SUBSTITUTED-PHENYL)-THIAZOLE DERIVATIVES SUITABLE FOR PEPTIC ULCER TREATMENT KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1984-03-21 EP disclosed
EP-0051409-A1 2-(Substituted-phenyl)-thiazole derivatives suitable for peptic ulcer treatment KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1982-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 CDC7 2482/4885DBF4 2072/4885PTPN11 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.